Abstract
Multiple endocrine neoplasia type 2 (MEN2) is a autosomal dominat inherited tumour-syndrome caused by germline activating mutations of the RET proto-oncogene on chromosome 10. It is clinically characterized by the presence of medullary thyroid carcinoma (MTC), bilateral pheochromocytoma and primary hyperparathyroidism (MEN2A) within a single patient. Three distinct clinical forms have been described depending on the phenotype: the classical MEN 2A, MEN 2B, an association of MTC, pheochromocytoma and mucosal neuroma, (FMTC) familial MTC with a low incidence of other endocrinopathies. Each variant of MEN2 results from different RET gene mutation, with a good genotype phenotype correlation. Genetic testing detects nearly 100% of mutation carriers and is considered the standard of care for all first degree relatives of patients with newly diagnosed MTC. Recommendations on the timing of prophylactic thyroidectomy and extent of surgery are based on a classification into four risk levels utilizing the genotype-phenotype correlations. MEN 2 gives a unique model for early prevention and cure of cancer and for stratified roles of mutation-based diagnosis of carriers.
Similar content being viewed by others
Abbreviations
- MEN:
-
Multiple endocrine neoplasia
- MTC:
-
Medullary thyroid carcinoma
- Ct:
-
Calcitonin
- Pheo:
-
Pheochromcytoma
- HPT:
-
Primary hyperparathyroidism
- FMTC:
-
Familial medullary thyroid carcinoma
- RET gene:
-
Rearranged during transfection gene
- CCH:
-
C-cell hyperplasia
References
Mulligan LM, Kwok JBJ, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2a (MEN 2A). Nature 363:458–469
Donis-Keller H, Dou S, Chi D et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genetics 2:851–856
Raue F, Frank-Raue K, Grauer A (1994) Multiple endocrine neoplasia type 2, clinical features and screening. Endocrin Metab Clin North Am 23:137–156
Brandi ML, Gagel R, Angeli A et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658–5671
Vasen HF, van der Feltz M, Raue F et al (1992) The natural course of multiple endocrine neoplasia type 2 b. Arch Intern Med 152:1250–1252
Berndt I, Reuter M, Saller B et al (1998) A new hotspot for mutations in the RET proto-oncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83:770–774
Kloos RT, Eng C, Evans DB et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565–612
Brauckhoff M, Machens A, Hess S et al (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144:1044–1051
Eng C, Mulligan LM, Smith DP et al (1995) Low frequency of germline mutations in the RET protooncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol 43:123–127
Machens A, Niccoli-Sire P, Hoegel J et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517–1525
LiVolsi VA (1997) C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 82:39–41
Grauer A, Raue F, Ziegler R (1998) Clinical usefullness of a new chemoluminescent two-site immunoassy for human calcitonin. Exp Clin Endorcinol Diabetes 106:353–359
Cohen R, Campos JM, Salaün C et al (2000) Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab 85:905–918
Mathew CG, Chin KS, Easton DF et al (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328:527–528
Romei C, Elisei R, Pinchera A et al (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81:1619–1622
Elisei R, Cosci B, Romei C et al (2008) Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682–687
Mulligan LM, Marsh DJ, Robinson BG et al (1995) Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Int Med 238:343–346
Eng C, Clayton D, Schuffenecker I et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276:1575–1579
Frank-Raue K, Höppner W, Frilling A et al (1996) Mutations of the RET proto-oncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. J Clin Endocrinol Metab 81:1780–1783
Machens A, Brauckhoff M, Holzhausen HJ et al (2005) Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab 90:3999–4003
Quayle FJ, Fialkowski EA, Benveniste R et al (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142:800–805
Schuffenecker I, Virally-Monod M, Brohet R et al (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. J Clin Endocrinol Metab 83:487–491
Kouvaraki MA, Shapiro SE, Perrier ND et al (2005) RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531–544
Frank-Raue K, Rondot S, Schulze E et al (2007) Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53:273–282
Moers AM, Lansvater RM, Schaap C et al (1996) Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family. Am J Med 101:635–641
Bolino A, Schuffenecker I, Luo Y et al (1995) RET mutations in exons 13 and 14 of FMTC patients. Oncogene 10:2415–2419
Smith DP, Houghton C, Ponder BA (1995) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15:1213–1217
Pacini F, Schlumberger M, Dralle H et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803
Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346:1459–1466
Frank-Raue K, Machens A, Scheuba C et al (2008) Difference in the development of medullary thyroid carcinoma among carriers of RET mutations in codon 790 and 791. Clin Endocrinol 69:259–263
Frank-Raue K, Buhr H, Dralle H et al (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol 155:229–236
Moley JF, Fialkowski EA (2007) Evidence-based approach to the management of sporadic medullary thyroid carcinoma. World J Surg 31:946–956
Giraudet AL, Al Ghulzan A, Auperin A et al (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239–246
Ball DW (2007) Medullary thyroid cancer: monitoring and therapy. Endocrinol Metab Clin N Am 36:823–837
Sherman SI (2009) Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 94:1493–1499
Raue F (1998) German medullary thyroid carcinoma/multiple endocrine neoplasia registry. Langenbeck‘s Arch Surg 383:334–336
Kebebew E, Ituarte PHG, Siperstein AE et al (2000) Medullary thyroid carcinoma, clinical characteristics, treatment, prognostic factors and a comparison of staging systems. Cancer 88:1139–1148
Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathological predictors of survival in 1252 cases. Cancer 107:2134–2142
de Groot JW, Plukker JTM, Wolffenbuttel BHR (2006) Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol 65:729–736
Bergholm U, Bergstrom R, Ekbom A (1997) Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer 79:132–138
Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic thyroidectomy in multiple endocrine neoplasia type 2. N Engl J Med 353:1105–1113
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Raue, F., Frank-Raue, K. Update multiple endocrine neoplasia type 2. Familial Cancer 9, 449–457 (2010). https://doi.org/10.1007/s10689-010-9320-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-010-9320-2